ImCheck Publishes Seminal Paper in Cell Reports Elucidating How Butyrophilins Activate Vγ9Vδ2 T cell Function Against Tumor Cells

July 13, 2021

ImCheck Therapeutics today announced the publication of preclinical data elucidating the fundamental role of butyrophilins (BTNs) in the activation of V gamma 9 V delta 2 (γ9δ2) T cells leading to an anti-tumor immune response in the peer-reviewed journal, Cell Reports. The publication, titled “BTN2A1, An Immune-checkpoint Targeting Vγ9Vδ2 T Cell Cytotoxicity Against Malignant Cells” summarizes the findings of the interaction between specific BTN subtypes that efficiently activate Vγ9Vδ2 T cells, an important subset of cytotoxic γδ T cells. In addition, the publication demonstrates that an anti-BTN2A1-specific antibody is able to inhibit the cytotoxic function of the Vγ9Vδ2 T cells. The article was authored by ImCheck scientists in collaboration with the laboratory of Prof. Daniel Olive, Professor of Immunology and Director of the Oncology Research Programs at Aix Marseille University and the company’s scientific founder.https://www.imchecktherapeutics.com/all-press-release/news/imcheck-publishes-seminal-paper-in-cell-reports-elucidating-how-butyrophilins-activate-vg9vd2-t-cell-function-against-tumor-cells/